Randomized, double-blind phase III (DUO-E) Newly diagnosed FIGO Stage III/IV or recurrent endometrial cancer of epithelial histology Carbo/paclitaxel x 6 => Placebo maintenance (I)

14 Apr

Uterine Cancer

New Indication: Trastuzumab Deruxtecan for her2-Expressing Advanced Uterine Cancer

Phase II, multicenter, single-arm study (STATICE) Pretreated advanced or recurrent HER2-expressing UCS Trastuzumab Deruxtecan: HER 2:1+ (low group, n=10) vs. HER 22+ (high grou

14 Apr

Head and Neck Cancer

New Indication: Axitinib and Avelumab for Adenoid Cystic Carcinoma

• Open-label,single-arm, phase 2 study Pretreated metastatic or recurrent ACC Axitinib + Avelumab q28 (n=28)

15 Mar

Waldenstrom macroglobulinemia

New Reference: Bortezomib, Rituximab, Cyclophosphamide for Waldenstrom

Prospectively Randomized , phase 3 trial Treatment naïve Waldenström's macroglobulinemia (WM) Bortezomib, dexamethasone, rituximab, and cyclophosphamide (B-DRC ) vs. DRC

10 Jan

Multiple Myeloma

New Drug: Teclistamab in R/R Multiple Myeloma

Single-arm, multi-cohort, open-label, multicenter, phase 1/2 study Relapsed or refractory myeloma after at least three therapy lines (n=165) Teclistamab sc weekly

10 Jan

Biliary Tract Cancer

New Drug: Futibatinib for Cholangicarcinoma

A single-arm, multicenter, phase 2 study Advanced/metastatic unresectable iCCA harboring FGFR2 gene fusions Disease progression after ≥1 line of systemic therapy Futibatinib 20 m

20 Aug

Renal Cell Carcinoma

New Reference: Pembrolizumab and Lenvatinib for Advanced Non-Clear-Cell RCC

Single-arm, open-label, multicenter, phase II trial Previously untreated stage IV non-clear cell renal cell carcinoma Pembrolizumab + Lenvatinib (n=158

16 Jul

Colorectal Cancer

New Indication: Pembrolizumab for MSI-High Colorectal Cancer

Randomised, open-label, phase 3 study (KEYNOTE-177) Untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer Pembrolizumab 200 mg every 3

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries